The international summit on genome editing kicked off on Tuesday at the headquarters of the National Academy of Sciences, Washington, D.C. Several scientists and researchers gathered for the three-day conference that will discuss the scientific, ethical and governance issues associated with human gene-editing technologies.
The summit particularly focuses on whether gene editing of human embryos for therapeutic reasons should be considered or ruled out altogether, The Guardian noted.
“The overriding question is when, if ever, we will want to use gene editing to change human inheritance," summit chair David Baltimore of Caltech said in his introductory remarks. “We are close to altering human heredity and we need to decide how we as a society are going to use this capability.”
According to The Australian, the process fixing defecting genes is very complicated, so much so that it has slowed down the development of genetic therapies. With gene editing technology, scientists use molecular tools to repair or replace a defective gene or delete it.
A new tool called CRISPR-Cas9 has been adopted by laboratories worldwide as it is faster, economical, and simple enough to use with minimal level of training. Scientists hope to use the tool for diseases like sickle cell, fixing the defective gene in someone's own blood-producing cells instead of implanting donated ones.
Jennifer Doudna of the University of California at Berkeley is one of the pioneers of the CRISPR technology. Doudna told reporters that it will still take several years before the tool can be used for treatment of human diseases, The Washington Post reported.
"We don't understand enough yet about the human genome, and how genes interact, and which genes give rise to certain traits to edit for human enhancement today," she said.
Marcy Darnovsky of the Center for Genetics and Society advocacy group, however, opposes heritable gene editing and calls it potentially a "society-altering technology."


Cyber attacks? Bioterrorism? To ‘Pace the Frontier’ of AI effectively, we must improve our anticipatory thinking
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
AI is supercharging money scams – here’s what you can do to protect yourself
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
Hyundai CEO Warns Chinese Automakers Could Disrupt US Market
Unsustainable – or manageable? We don’t yet know how data centres will impact Australia’s environment
US Federal Register Drops Alibaba Qwen AI Search Tool
FDA Weighs Safety Standards for Psychedelic Therapies
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility?
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline
Apple Pay Set for India Launch With Axis Bank
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race
France Urges Faster AI Push Despite Safety Risks
NASA, Boeing Discuss Expanding Starliner Missions
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Physicists zoom into the birth of cosmic rainstorms with new CERN study
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 



